Market Overview

CD33-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells - Research and Markets

Share:
DUBLIN--(BUSINESS WIRE)--

Research and Markets has announced the addition of the "CD33-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells" report to their offering.

This pdf report contains information about TCR & CAR engineered T-cells and NK cells released during the month of September 2016. This issue forms part of the subscription service R&D and Business Tracker for TCR & CAR T-Cells and NK Cells which is listed in the "also available" below.

Featured presentations of September 2016 include the pipeline of CD33-targeted immunotherapeutics, the profile of US biotech Eureka Therapeutics and the profile of anti-glypican 3 CAR-T CSG-GPC3 from CARsGen Therapeutics.

The September 2016 issue of our R&D and Business Tracker service about TCR & CAR engineered T-cells and NK cells contains:

R&D and Technology Tracker

- Pipeline changes

- Regulatory news

- Technology validations

Business Tracker for:

- Company updates

- Collaboration

- Licensing

- Merger & acquisitions

- Financing

Clinical Trial Tracker:

- Scientific Publication Tracker

- Featured Cell Therapy Profile: CSG-GPC3

- Featured Company Profile: Eureka Therapuetics

- Featured Target or Technology Pipeline: CD33-Targeted Immunotherapeutics

CD33-Targeted Immunotherapeutics:

- Antibody-Drug Conjugates

- Radio-Immunotherapeutics

- Fc-Engineered Antibodies

- T-Cell and NK Cell Redirecting Bispecific Antibodies

- CAR T-Cells

For more information about this report visit http://www.researchandmarkets.com/research/cwdn28/cd33targeted

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cars

View Comments and Join the Discussion!